You can buy or sell PRTK and other stocks, options, ETFs, and crypto commission-free!
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. Read More The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Seeking AlphaMar 18
Paratek Pharmaceuticals announces management change
Paratek Pharmaceuticals (PRTK -3.4% ) announces resignation of Douglas Pagán, CFO, effective April 5, 2019 The Company also announces that Sarah Higgins, Paratek’s Vice President and Controller, will serve as the company's Principal Financial Officer and Principal Accounting Officer as the company conducts a search for a new CFO...
Stock Price, News, & Analysis for Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tet...
Expected May 8, Pre-Market